Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer.

Mark K DohertyVincent C TamMairéad Geraldine McNamaraRaymond JangDavid HedleyEric ChenNeesha DhaniPatricia TangHao-Wen SimGrainne M O'KaneStephanie DeLucaLisa WangTheresa PedutemJennifer J Knox

Published in: British journal of cancer (2022)

Adding sequential or continuous selumetinib to CisGem failed to improve efficacy and increased toxicity in patients with advanced BTC.

Keyphrases